Dr Reddys Laboratories Ltd has introduced for the first time in India, a European research product Doxofylline, a novel second-generation xanthine bronchodilator. The company has introduced this product under license agreement from Kent Union Ltd, Hong Kong and marketing cooperation with the Netherlands-based pharma company -Eurodrug Laboratories BV.

Doxofylline is introduced under the brand name 'Doxobid' and will be available in a special pack of 10's in 400 mg dosage. Doxobid is meant to treat patients suffering from asthma & COPD (Chronic Obstructive Pulmonary Disease), said the release.

The total market of methyl xanthines (combinations & plain) is estimated to be around at Rs 600 million.